Benchmark reiterates Buy rating on Biofrontera stock amid tariff concerns
PositiveFinancial Markets

Benchmark has reaffirmed its Buy rating on Biofrontera stock, despite ongoing concerns about tariffs. This decision reflects confidence in the company's potential for growth and resilience in the face of economic challenges. Investors may find this reassuring as it suggests that Biofrontera is well-positioned to navigate market fluctuations.
— Curated by the World Pulse Now AI Editorial System